The biotechnology firm clarified that the correction is limited to the digital access point for the legal documentation. No other information from the original announcement, which detailed the company's ongoing litigation over alleged naked short selling practices, has been altered or updated. The Second Amended Complaint, listed as Civil Action No. 26-549-CFC, remains accessible via the company's investor relations portal or the federal court's public docket system.

Lunai Bioworks, headquartered in California and traded on the NASDAQ under the ticker LNAI, specializes in drug discovery for central nervous system disorders. Formed by the 2025 merger of Renovaro and BioSymetrics, the company utilizes its proprietary Augusta AI platform to analyze patient data for potential therapeutic breakthroughs in conditions such as Alzheimer’s and Parkinson’s disease.